Medindia

X

Reportlinker Adds the Blood Industry

Wednesday, May 11, 2011 General News J E 4
Advertisement

NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The Blood Industry

http://www.reportlinker.com/p096627/The-Blood-Industry.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Sup

REPORT HIGHLIGHTS

* The global blood market includes products used for collecting, typing, processing, and transfusing of blood and the sale of blood therapeutics. This market was worth $30 billion in 2010 and is forecast to increase at an 8.4% compound annual growth rate (CAGR) to reach $45 billion in 2015.

* Blood therapeutic products, including immunoglobulins, coagulation factors, albumin, fibrin sealants, and antithrombin products, are projected to grow at a compound annual growth rate (CAGR) of 10.8% over the 5-year forecast period. This sector was valued at nearly $16 billion in 2010 and is expected to reach $26 billion in 2015.

* Sales for blood processing, collection, and typing/testing reached $14 billion in 2010. This market is forecast to grow at a 5.5% compound annual growth rate (CAGR) to reach more than $18 billion in 2015.

REPORT SCOPE

INTRODUCTION

REASONS FOR DOING THE STUDY

A safe and adequate blood supply is essential to the practice of modern medicine. Ensuring adequate supplies of trustworthy blood and derivative products has lead nations and companies to create a multibillion-dollar business that reaches around the globe.

The global blood industry encompasses the collection, typing, testing, and processing of blood and the creation of blood derivatives to help individuals with varying blood problems. The purpose of this study is to detail advances in these areas and their impact on the blood industry.

During the past 10 years, since BCC first looked at this market, mergers and acquisitions have created an industry dominated by less than 10 major companies. This consolidation and advances in technology have allowed industry participants to obtain more red blood cells from fewer donors. Technological advances have also allowed for greater economies and increased safety in the blood supply.

STUDY GOALS AND OBJECTIVES

With its broad scope and in-depth analyses, this study will be a valuable resource to anyone involved with or interested in the blood industry. This study will provide information on:

* Structure and current market size of the blood industry, with forecasts through 2015

* Analysis and projections of various segments of the industry such as collection, typing, testing, and blood therapeutics

* Blood usage patterns and trends

* Government and regulatory controls

* Impact of diseases on the blood industry

* Major players and their relative market shares and market potential

* Current product lines and examination of newly emerging products and technologies

* State of the international markets for various blood and blood-related products

* Newly issued patents relating to blood therapeutics, processing, screening, and collection technologies.

The study will prove valuable to a variety of readers, including industry executives, managers and planners, researchers, industry analysts, and investors. The projections, forecasts, and trend analyses found in this report provide readers with the necessary data and information for careful decision- making.

SCOPE OF REPORT

This report offers global and U.S. projections, by product segment, from 2010 through 2015, including supporting analyses for projections. Product segments covered consist of blood and plasma collection, blood and plasma processing, blood therapeutic products, plasma therapeutic products, and emerging trends and products.

The arrangement of this report offers an overview of the key elements in the blood collection and processing businesses: blood typing techniques and markets, and plasma fractionation. International markets are discussed, and information is provided on industry structure and the regulatory environment outside the U.S.

Profiles of more than 30 leading companies involved with blood collection, processing, and therapeutics are included. The report provides information on company placement within the market and strategic analyses of the companies' available and emerging products.

METHODOLOGIES AND INFORMATION SOURCES

Information for this report was derived from a variety of primary and secondary research sources, including industry analysts, annual reports and SEC reports, the American Red Cross (ARC), the American Association of Blood Banks (AABB), the Plasma Protein Therapeutics Association (PPTA), the National Institutes of Health (NIH), the Centers for Disease Control (CDC), other government agencies, and journal articles. Secondary sources include literature searches, product literature, and press releases.

When precise information was not available, a consensus was made using reasonable assumptions and estimates based on historical data.

CHAPTER ONE: INTRODUCTION 1

REASONS FOR DOING THE STUDY 1

STUDY GOAL AND OBJECTIVES 1

SCOPE OF REPORT 2

METHODOLOGIES AND INFORMATION SOURCES 2

ANALYST CREDENTIALS 2

RELATED BCC REPORTS 3

BCC ONLINE SERVICES 3

DISCLAIMER 3

CHAPTER TWO: SUMMARY 4

MAJOR FINDINGS 4

SUMMARY TABLE GLOBAL BLOOD COLLECTION, PROCESSING,

AND THERAPEUTICS MARKET, THROUGH 2015 ($ MILLIONS) 5

SUMMARY FIGURE GLOBAL BLOOD MARKET, BY REGION, 2010

AND 2015 (%) 5

SUMMARY FIGURE (CONTINUED) 6

CHAPTER THREE: OVERVIEW 7

HISTORY OF THE BLOOD INDUSTRY 7

TABLE 1 TIMELINE OF THE BLOOD INDUSTRY 8

CONSOLIDATION IN THE INDUSTRY 9

TABLE 2 SELECTED ACQUISITIONS AND MERGERS IN THE

GLOBAL BLOOD INDUSTRY, 2006-2011 ($ MILLIONS) 10

DYNAMICS OF BLOOD DONATION 10

BLOOD COLLECTION AND PROCESSING MARKET STRUCTURE 11

AND SIZE 11

TABLE 3 US BLOOD COLLECTION AND PROCESSING PRODUCTS

MARKET, THROUGH 2015 ($ MILLIONS) 11

BLOOD AND ITS COMPONENTS 11

TABLE 4 COMPOSITION OF BLOOD 12

PLASMA 12

Uses for Plasma Proteins 13

TABLE 5 PERCENT OF PLASMA PROTEINS AND THE DISEASES

AND DISORDERS THEY TREAT 13

Immunoglobulin Products 14

CELLULAR ELEMENTS 14

Red Blood Cells 14

White Blood Cells 15

Platelets 15

TRANSFUSION-ASSOCIATED RISKS 16

DISEASES CONTRACTED FROM BLOOD TRANSFUSION

AND RELATED IDENTIFICATION TESTING 16

TABLE 6 DISEASES CONTRACTED FROM BLOOD TRANSFUSIONS 16

TABLE 6 (CONTINUED) 17

HIV/AIDS 17

TABLE 7 CBER-LICENSED HIV DONOR SCREENING TESTS 18

TABLE 7 (CONTINUED) 19

Hepatitis A 20

Worldwide Incidences of Hepatitis A 20

Hepatitis B (HBV) 20

TABLE 8 CBER-LICENSED SCREENING TEST FOR HEPATITIS B 21

Hepatitis C 22

TABLE 9 CBER-LICENSED SCREENING TESTS FOR HEPATITIS C 22

Hepatitis D 23

Hepatitis E 23

Human T-Cell Lymphotropic Virus (HTLV-I, II) 23

TABLE 10 CBER-LICENSED SCREENING TESTS FOR HTLV-I AND

HTLV-II 24

Cytomegalovirus 24

TABLE 11 CBER-LICENSED SCREENING TESTS FOR CMV 25

TABLE 12 CBER-LICENSED SCREENING TESTS FOR WEST NILE

VIRUS 26

"Mad Cow Disease"/Creutzfeldt-Jakob Disease (CJD) 26

Syphilis 27

TABLE 13 CBER-LICENSED SCREENING TESTS FOR SYPHILIS 27

Chagas Disease 27

TABLE 14 CBER-LICENSED SCREENING TESTS FOR

TRYPANOSOMA CRUZI (CHAGAS DISEASE) 28

TABLE 15 CBER-LICENSED SCREENING TEST, BY TYPE 28

TABLE 15 (CONTINUED) 29

FIGURE 1 TYPES OF BLOOD SCREENING TESTS (%) 30

CREATING A VIRUS-FREE BLOOD SUPPLY 30

CERUS CORP 31

COST OF A VIRUS-FREE BLOOD SUPPLY 31

PLASMA TREATMENTS TO INACTIVATE VIRUSES 31

Trinitrobutyl Phosphate and Sodium Cholate 31

Methylene Blue-Treated Plasma 32

Amatosalen HCL-Treated Plasma 32

NEGATIVE REACTIONS FROM BLOOD TRANSFUSIONS 33

BLOOD/PLASMA COMPONENT RISKS 34

CHAPTER FOUR: BLOOD COLLECTION, TYPING, AND PROCESSING 35

TABLE 16 PROJECTED GLOBAL MARKET FOR BLOOD/PLASMA

COLLECTION, TYPING AND TESTING, AND PROCESSING

EQUIPMENT AND SUPPLIES, THROUGH 2015 ($ MILLIONS) 35

BLOOD COLLECTION 36

METHODS FOR COLLECTING BLOOD 36

TABLE 17 PROJECTED GLOBAL MARKET FOR MANUAL AND

AUTOMATIC BLOOD COLLECTION EQUIPMENT AND SUPPLIES,

THROUGH 2015 ($ MILLIONS) 37

MANUAL COLLECTION 37

AUTOMATED COLLECTION 37

Plasmapheresis 38

Plateletpheresis 38

Leukopheresis 39

Red Blood Cell Apheresis 39

BLOOD SALVAGE EQUIPMENT 39

TABLE 18 PROJECTED GLOBAL MARKET FOR AUTOMATED

BLOOD SALVAGE EQUIPMENT, THROUGH 2015 ($ MILLIONS) 40

BLOOD BAGS 40

TABLE 19 PROJECTED GLOBAL MARKET FOR BLOOD BAGS,

THROUGH 2015 ($ MILLIONS) 41

BLOOD FILTERS 41

TABLE 20 PROJECTED GLOBAL MARKET FOR BLOOD FILTERS,

THROUGH 2015 (MILLIONS) 42

TRANSFUSION SETS, ACCESSORIES 42

OTHER EQUIPMENT 42

TABLE 21 PROJECTED GLOBAL MARKET FOR OTHER

COLLECTION EQUIPMENT INCLUDING BLOOD TRANSFUSION

SETS AND ACCESSORIES, THROUGH 2015 ($ MILLIONS) 43

MARKET DRIVERS IN BLOOD COLLECTION 43

US BLOOD COLLECTION ORGANIZATIONS 43

FOR-PROFIT BLOOD COLLECTION CONTROVERSY 44

NONPROFIT BLOOD COLLECTION IN THE US 44

American Red Cross (ARC) 44

Community Blood Banks 44

Hospitals 45

Other Blood Collection Sites 45

US BLOOD DONATION DEMOGRAPHICS 45

DONOR RECRUITMENT AND REGULATIONS 45

BLOOD SCREENING AND EVALUATION 46

BLOOD COLLECTION EFFORTS THROUGHOUT THE WORLD 46

SOUTH AMERICA/CENTRAL AMERICA 47

ASIA 47

PACIFIC REGION 47

AFRICA 48

CANADA 48

EUROPE 48

United Kingdom 48

France 48

GLOBAL NATURE OF THE PLASMA INDUSTRY 49

PLASMA DONORS 49

COMMERCIAL NATURE OF PLASMAPHERESIS 50

PLASMA COLLECTION CENTERS IN THE US 50

National Donor Referral Registry 51

PLASMA FRACTIONATORS 51

DISTRIBUTORS/BROKERS 52

BLOOD TYPING 52

METHODS OF TYPING 52

Slide/Tile Testing 53

Tube Testing 53

Microplate Testing Methods 53

AUTOMATED BLOOD TYPING AND SCREENING METHODS 54

Immucor 54

Ortho-Clinical Diagnostics 54

Abbott 55

BLOOD TRANSFUSION TESTING 55

MANUAL CROSSMATCH TECHNIQUES 55

Major Crossmatch 55

Minor Crossmatch 56

Antibody Screening 56

Coombs Test 56

BLOOD TESTING 56

TABLE 22 TESTS ROUTINELY PERFORMED ON BLOOD

DONATIONS 57

TABLE 23 BLOOD TYPE ANTIGEN/ANTIBODY REACTIONS 57

TABLE 24 PROJECTED GLOBAL MARKET FOR BLOOD TYPING AND

TESTING, BY GEOGRAPHICAL AREA, THROUGH 2015 ($

MILLIONS) 58

FIGURE 2 PROJECTED GLOBAL MARKET FOR BLOOD TYPING AND

TESTING, 2010 AND 2015 (%) 58

FIGURE 2 (CONTINUED) 59

BLOOD PROCESSING 59

PREPARATION AND USE OF THE COMPONENTS 59

Red Blood Cells 60

Platelets 60

MARKET PARTICIPANTS 60

Haemonetics 60

PCS2 61

TCD Total Containment Unit 61

MCS+ 8150 System 61

Cell Saver System 61

OrthoPAT System 61

ACP 215 System 61

Fenwal 62

Autopheresis-C 62

Alyx Component Collection System 62

CS-3000 Plus Blood Cell Separator 62

Amicus Separator 62

Gambro BCT 63

Trima Accel Collection System 63

COBE Spectra Apheresis System 63

The Elutra Cell Separation System 63

GLOBAL BLOOD MANAGEMENT ISSUES 63

AVAILABILITY 63

BLOODLESS SURGERY 64

FEWER OPEN SURGICAL PROCEDURES 65

SAFETY ISSUES/RISK MANAGEMENT 65

Improved Donor Screening 65

Better Viral Testing 66

Encouraging Repeat Donors 66

Improving Viral Inactivation Processes 66

Selective Use of Blood Derivative Products 66

CHAPTER FIVE: BLOOD THERAPEUTICS 67

TABLE 25 BLOOD PRODUCTS TRANSFUSED FOR THEIR

THERAPEUTIC USES 67

WHOLE BLOOD 67

PACKED RED BLOOD CELLS 68

PLATELETS 68

LEUKOCYTES 69

FRESH FROZEN PLASMA 69

SELECTED USES OF FFP 70

CRYOPRECIPITATE 70

WASHED CELLS 70

DEGLYCEROLIZED CELLS 71

OTHER BLOOD COMPONENTS 71

GRANULOCYTES 71

GAMMA-IRRADIATED BLOOD 71

DISTRIBUTION OF COLLECTED BLOOD 71

TABLE 26 AVERAGE COST OF TRANSFUSION TO THE PATIENT IN

THE US, BY PRODUCT TYPE, 2011 ($) 72

PLASMA AND PLASMA-DERIVED PRODUCTS 72

GLOBAL PLASMA COLLECTION 73

PLASMA MARKET SIZE 73

TABLE 27 PROJECTED GLOBAL PLASMA MARKET, THROUGH 2015

($ MILLIONS) 73

FIGURE 3 PLASMA PRODUCTS MARKET SHARE, BY COMPANY,

2010 (%) 74

COAGULATION FACTORS 74

IMMUNE SERUM GLOBULIN/INTRAMUSCULAR IMMUNE

GLOBULINS (IMIG)/INTRAVENOUS IMMUNE

GLOBULIN (IVIG) 75

Market Shortages of IVIG 75

FACTOR VIII 76

FACTOR IX AND FACTOR IX COMPLEX 76

FACTOR VIIA 76

FIBRIN/THROMBIN 76

THERAPEUTIC APHERESIS 77

CLOTTING FACTORS 77

TABLE 28 BLOOD CLOTTING FACTORS 78

Hemophilia 78

TABLE 29 GLOBAL PREVALENCE OF HEMOPHILIA, 2009

(MILLIONS) 79

CLOTTING FACTOR MARKET DEMAND AND MARKET

SIZE 79

TABLE 30 PROJECTED GLOBAL MARKET FOR PLASMA-DERIVED

AND RECOMBINANT CLOTTING FACTORS, THROUGH 2015 ($

MILLIONS) 80

Factor VIII 80

TABLE 31 FDA-APPROVED FACTOR VIII PRODUCTS 81

Advate 81

Helixate FS 82

Kogenate FS 82

Recombinate 82

ReFacto 82

GLOBAL SHARE IN FACTOR VIII MARKET 83

FIGURE 4 LEADING FACTOR VIII MANUFACTURERS, 2010 (%) 83

TABLE 32 PROJECTED US MARKET FOR FACTOR VIII, THROUGH

2015 ($ MILLIONS) 84

Factor IX 84

TABLE 33 PROJECTED GLOBAL MARKET FOR FACTOR IX,

THROUGH 2015 ($ MILLIONS) 84

TABLE 34 FDA-APPROVED FACTOR IX PRODUCTS, 2009 85

Factor VIIa 85

TABLE 35 PROJECTED GLOBAL MARKET FOR FACTOR VIIA,

THROUGH 2015 ($ MILLIONS) 86

FIGURE 5 GLOBAL SALES OF FACTOR VIIA, BY GEOGRAPHIC

REGION, 2010 (%) 86

FIGURE 5 (CONTINUED) 87

ALBUMIN 87

RECOMBINANT HUMAN ALBUMIN 88

Recombinant Human Albumin Market 88

ALBUMIN MARKET DYNAMICS 88

TABLE 36 CURRENTLY MARKETED HUMAN ALBUMIN AND PPF

PRODUCTS, 2010 89

ALBUMIN AND PPF MARKET SIZE 89

TABLE 37 PROJECTED GLOBAL MARKET FOR HUMAN SERUM

ALBUMIN AND PPF, THROUGH 2015 ($ MILLIONS) 90

PROTHROMBIN COMPLEX CONCENTRATE 90

TABLE 38 FDA-APPROVED PROTHROMBIN COMPLEX

CONCENTRATE PRODUCTS 90

FIBRIN SEALANTS AND THROMBIN 91

FIBRIN-BASED WOUND CLOSURE PRODUCT MARKET 91

Cyanoacrylate 92

TABLE 39 PROJECTED GLOBAL MARKET FOR FIBRIN-BASED

SEALANTS, THROUGH 2015 ($ MILLIONS) 92

ANTITHROMBIN TREATMENTS 93

TREATMENTS FOR HD 93

Plasma Antithrombin 93

Recombinant Human Antithrombin (rhAT) 93

Talecris Biotherapeutics 93

GTC Biotherapeutics 94

GlaxoSmithKline (Arixtra) 94

GLOBAL MARKET FOR ANTITHROMBIN 94

TABLE 40 PROJECTED GLOBAL MARKET FOR ANTITHROMBIN,

THROUGH 2015 ($ MILLIONS) 95

IMMUNOGLOBULINS 95

TABLE 41 FDA-APPROVED IMMUNOGLOBULINS 96

TABLE 42 PROJECTED GLOBAL MARKET FOR

IMMUNOGLOBULINS, THROUGH 2015 ($ MILLIONS) 97

POLYVALENT IMMUNOGLOBULINS 97

TABLE 43 SELECTED CONDITIONS TREATED WITH IVIG 98

The Projected Global IVIG Therapy Market 98

TABLE 44 PROJECTED GLOBAL MARKET FOR IVIG THERAPY,

THROUGH 2015 ($ MILLIONS) 98

HYPERIMMUNE IMMUNOGLOBULINS 99

TABLE 45 FDA-APPROVED HYPERIMMUNE IMMUNOGLOBULINS 99

TABLE 45 (CONTINUED) 100

GLOBAL MARKET FOR HYPERIMMUNOGLOBULINS 100

TABLE 46 PROJECTED GLOBAL MARKET FOR

HYPERIMMUNOGLOBULINS, THROUGH 2015 ($ MILLIONS) 101

FIGURE 6 GLOBAL MARKET FOR IMMUNOGLOBULINS, BY TYPE,

2009 AND 2015 ($ MILLIONS) 101

Respiratory Syncytial Virus (RSV) 102

TABLE 47 PROJECTED GLOBAL MARKET FOR RSV

IMMUNOGLOBULIN, THROUGH 2015 ($ MILLIONS) 102

Alpha-1-Proteinase Inhibitor 102

TABLE 48 PROJECTED GLOBAL MARKET FOR ALPHA-1-

PROTEINASE INHIBITOR, THROUGH 2015 ($ MILLIONS) 103

Rho(D) 103

TABLE 49 PROJECTED GLOBAL MARKET FOR RHO(D), THROUGH

2015 ($ MILLIONS) 104

Hepatitis B Immune Globulin 104

TABLE 50 PROJECTED GLOBAL MARKET FOR HBV

IMMUNOGLOBULINS, THROUGH 2015 ($ MILLIONS) 104

CMV Immunoglobulin 105

TABLE 51 PROJECTED GLOBAL MARKET FOR CMV

IMMUNOGLOBULIN, THROUGH 2015 ($ MILLIONS) 105

Tetanus Immunoglobulin 105

TABLE 52 PROJECTED GLOBAL MARKET FOR TETANUS

IMMUNOGLOBULIN, THROUGH 2015 ($ MILLIONS) 106

Rabies Immunoglobulin 106

TABLE 53 PROJECTED GLOBAL MARKET FOR RABIES

IMMUNOGLOBULIN, THROUGH 2015 ($ MILLIONS) 107

Varicella Immunoglobulin 107

Vaccinia Immune Globulin Intravenous (VIG) 107

CHAPTER SIX: BLOOD INDUSTRY REGULATION 108

REGULATION OF THE US BLOOD BUSINESS 108

TABLE 54 US FEDERAL ORGANIZATIONS RESPONSIBLE FOR

BLOOD SAFETY 108

TABLE 54 (CONTINUED) 109

STATUTORY AUTHORITY OF THE FDA 109

Center for Biologics Evaluation and Research 109

Office of Regulatory Affairs (ORA) 110

Office of Biologics, the Division of Blood and Blood

Products 110

TABLE 55 FDA AUTHORITY IN REGULATING BLOOD BANKING

AND BLOOD PRODUCTS 111

MAJOR REGULATIONS AND POLICIES FOR THE US BLOOD

SUPPLY 111

THE CLINICAL LABORATORY IMPROVEMENT ACT OF

1988 (CLIA) 111

THE FDA APPROACH TO BLOOD REGULATION 112

TABLE 56 MAIN BLOOD REGULATION ISSUES IDENTIFIED BY THE

FDA 113

TEAM BIOLOGICS 113

REGULATION IMPLEMENTATION 114

TABLE 57 14 MAJOR AREAS OF CONCERN FOR INSPECTING

BLOOD FACILITIES 114

TABLE 57 (CONTINUED) 115

OTHER US ORGANIZATIONS INVOLVED IN BLOOD

REGULATION 115

National Heart, Lung, and Blood Institute (NHLBI) 115

Blood Disease and Resources Program 116

Occupational Safety and Health Administration (OSHA) 116

Centers for Medicare and Medicaid Services (CMS) 116

State Regulatory Agencies 117

VOLUNTARY REGULATION BY PROFESSIONAL AND

TRADE ASSOCIATIONS 117

American Association of Blood Banks (AABB) 117

National Donor Deferral Registry (NDDR) 118

Quality Plasma Program 118

America's Blood Centers (ABC) 119

Plasma Products Therapeutics Association (PPTA 119

EUROPEAN UNION (EU) REGULATIONS 119

THE INTERNATIONAL SOCIETY FOR BLOOD TRANSFUSION

(ISBT) 128 120

REGULATION IN JAPAN 120

REGULATION IN CHINA 120

THE FUTURE OF GLOBAL BLOOD REGULATIONS 121

CHAPTER SEVEN: BLOOD PRODUCTS TECHNOLOGY 122

FRACTIONATION METHODS 122

COHN METHOD 122

ADVANCED FRACTIONATION METHODS 122

Chromatography Methods 123

AMPLIFICATION METHODS 123

POLYMERASE CHAIN REACTION 123

NUCLEI AMPLIFICATION TECHNOLOGY 123

IMMUNOASSAY METHODS 124

ENZYME IMMUNOASSAY 124

Basic EIA 124

FIGURE 7 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS 125

Second Antibody Precipitation Method 125

Double Antibody Sandwich Method 126

Reverse Sandwich Method 126

Reverse Sandwich Inhibition Method 126

AGGLUTINATION 126

CHEMILUMINESCENCE (CHLIA) 127

ENDOTOXIN TESTING 127

CHAPTER EIGHT: BLOOD RESEARCH AND DEVELOPMENT 128

JEROME H HOLLAND LABORATORY (ARC) 128

NATIONAL BLOOD FOUNDATION (NBF) 128

CENTER FOR BLOOD RESEARCH (CBR) 128

STEM CELL RESEARCH AT THE CBR 129

FDA BLOOD RESEARCH PRODUCTS 130

TABLE 58 SELECTED BLOOD RESEARCH FROM FDA, 2010 130

TABLE 58 (CONTINUED) 131

STEM CELL DEVELOPMENTS OUTSIDE THE US 132

NOVEL BIOENGINEERING TECHNOLOGIES 132

RESEARCH ON ALZHEIMER'S AND CIRRHOSIS OF THE LIVER 133

CURRENT RESEARCH ON BLOOD SUBSTITUTES 133

EMERGING PLATELET TREATMENTS 134

RED BLOOD CELLS 135

THE VETERINARY BLOOD MARKET 136

TABLE 59 REGIONAL US VETERINARY BLOOD BANKS 136

CHAPTER NINE: PATENTS 137

TABLE 60 RECENTLY ISSUED PATENTS, JANUARY 2005 THROUGH

JANUARY 2011 137

TABLE 61 PATENTS BY COMPANY ASSIGNEE, JANUARY 2005

THROUGH JANUARY 2011 138

TABLE 62 PATENTS ISSUED BETWEEN 2005 AND 2011: PLASMA

DERIVATIVES 139

TABLE 63 PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD

COLLECTION, SAMPLING EQUIPMENT 140

TABLE 63 (CONTINUED) 141

TABLE 63 (CONTINUED) 142

TABLE 63 (CONTINUED) 143

TABLE 63 (CONTINUED) 144

TABLE 63 (CONTINUED) 145

TABLE 64 PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD

FILTRATION, FLUID SEPARATION EQUIPMENT 146

TABLE 64 (CONTINUED) 147

TABLE 64 (CONTINUED) 148

TABLE 64 (CONTINUED) 149

TABLE 64 (CONTINUED) 150

TABLE 64 (CONTINUED) 151

TABLE 64 (CONTINUED) 152

TABLE 65 PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD

VOLUME ENHANCERS 153

TABLE 66 PATENTS ISSUED BETWEEN 2005 AND 2011: NUCLEIC

ACID AMPLIFICATION 153

TABLE 66 (CONTINUED) 154

TABLE 67 PATENTS ISSUED BETWEEN 2005 AND 2011: BLOOD

TREATMENTS 155

TABLE 67 (CONTINUED) 156

TABLE 68 PATENTS ISSUED BETWEEN 2005 AND 2011:

ADDITIONAL POTENTIAL PRODUCTS 157

TABLE 68 (CONTINUED) 158

TABLE 68 (CONTINUED) 159

TABLE 68 (CONTINUED) 160

CHAPTER TEN: COMPANY PROFILES 161

ABBOTT LABORATORIES 161

BUSINESS OVERVIEW 161

FINANCIALS 161

PRODUCTS 161

ALPHA THERAPEUTICS CORP (SEE GRIFOLS) 162

AMERICA'S BLOOD CENTERS 162

BUSINESS OVERVIEW 162

FINANCIALS 162

PRODUCTS 163

AMERICAN ASSOCIATION OF BLOOD BANKS (AABB) 163

BUSINESS OVERVIEW 163

FINANCIALS 163

PRODUCTS 163

AMERICAN RED CROSS 164

BUSINESS OVERVIEW 164

FINANCIALS 164

PRODUCTS 164

BAXTER INTERNATIONAL, INC 165

BUSINESS OVERVIEW 165

FINANCIALS 165

PRODUCTS 165

BECKMAN COULTER 166

BUSINESS OVERVIEW 166

FINANCIALS 167

PRODUCTS 167

BECTON DICKINSON AND COMPANY 167

BUSINESS OVERVIEW 167

FINANCIALS 167

PRODUCTS 168

BIO PRODUCTS LABORATORIES 168

BUSINESS OVERVIEW 168

FINANCIALS 168

PRODUCTS 168

BIO-RAD LABORATORIES, INC 169

BUSINESS OVERVIEW 169

FINANCIALS 169

PRODUCTS 169

BIOTEST AG 169

BUSINESS OVERVIEW 170

FINANCIALS 170

PRODUCTS 170

CARIDIANBCT INC 170

BUSINESS OVERVIEW 171

FINANCIALS 171

PRODUCTS 171

CERUS CORP 172

BUSINESS OVERVIEW 172

FINANCIALS 172

PRODUCTS 172

CHIRON CORP (SEE NOVARTIS DIAGNOSTICS) 172

CSL BEHRING 172

BUSINESS OVERVIEW 173

FINANCIALS 173

PRODUCTS 173

DAXOR CORP 174

BUSINESS OVERVIEW 174

FINANCIALS 174

PRODUCTS 174

DIAGAST 175

BUSINESS OVERVIEW 175

FINANCIALS 175

PRODUCTS 175

FENWAL BLOOD TECHNOLOGIES, INC 176

BUSINESS OVERVIEW 176

FINANCIALS 176

PRODUCTS 176

FRESENIUS KABI AG 176

BUSINESS OVERVIEW 177

FINANCIALS 177

PRODUCTS 177

GEN-PROBE, INC 177

BUSINESS OVERVIEW 177

FINANCIALS 178

PRODUCTS 178

GRIFOLS BIOLOGICALS, INC 178

BUSINESS OVERVIEW 178

FINANCIALS 179

PRODUCTS 179

HAEMONETICS, INC 179

BUSINESS OVERVIEW 179

FINANCIALS 180

PRODUCTS 180

Cell Saver System 181

OrthoPAT System 181

ACP 215 System 181

HEMAGEN DIAGNOSTICS, INC 181

BUSINESS OVERVIEW 181

FINANCIALS 182

PRODUCTS 182

HEMOCUE AB 182

BUSINESS OVERVIEW 182

FINANCIALS 182

PRODUCTS 182

IMMUCOR, INC 183

BUSINESS OVERVIEW 183

FINANCIALS 183

PRODUCTS 183

KAWASUMI LABORATORIES, INC 183

BUSINESS OVERVIEW 184

FINANCIALS 184

PRODUCTS 184

LUMINEX CORPORATION 184

BUSINESS OVERVIEW 185

FINANCIALS 185

PRODUCTS 185

MACOPHARMA USA (FORMERLY UNITED PHARMA) 186

BUSINESS OVERVIEW 186

FINANCIALS 186

PRODUCTS 186

MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABS 186

BUSINESS OVERVIEW 186

FINANCIALS 187

PRODUCTS 187

NOVARTIS DIAGNOSTICS 187

BUSINESS OVERVIEW 187

FINANCIAL INFORMATION 188

PRODUCTS 188

NOVO NORDISK 189

BUSINESS OVERVIEW 189

FINANCIALS 189

PRODUCTS 189

OCTAPHARMA 189

BUSINESS OVERVIEW 190

FINANCIALS 190

PRODUCTS 190

OLYMPUS AMERICA, INC (SEE BECKMAN COULTER) 190

ONE LAMBDA, INC 190

BUSINESS OVERVIEW 190

FINANCIALS 191

PRODUCTS 191

ORTHO-CLINICAL DIAGNOSTICS 191

FINANCIALS 192

PRODUCTS 192

PALL CORP 192

BUSINESS OVERVIEW 192

FINANCIALS 192

PRODUCTS 193

PFIZER 193

BUSINESS OVERVIEW 193

FINANCIALS 193

PRODUCTS 194

TALECRIS BIOTHERAPEUTICS 194

BUSINESS OVERVIEW 194

FINANCIALS 194

PRODUCTS 195

TERUMO MEDICAL CORP 195

BUSINESS OVERVIEW 195

FINANCIALS 196

PRODUCTS 196

THERMOGENESIS CORP 196

BUSINESS OVERVIEW 196

FINANCIALS 197

PRODUCTS 197

To order this report:

Blood Supply, Tissue Banking and Transplantation Industry: The Blood Industry

Blood Supply, Tissue Banking and Transplantation Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Pharmaceutical Key Trends 2011 -...
S
OncoSec Announces Leadership Team Appointments